Pyxis Oncology Shares Slide on Steeper 1Q Loss

Dow Jones

05/15

By Kelly Cloonan

Shares of Pyxis Oncology declined after the company logged a steeper first-quarter loss, narrowly missing Wall Street's expectations.

The stock slid 15% to $2.24 on Thursday. Shares have surged 94% year to date.

The company, which is developing cancer treatments, posted a loss of $23.3 million, or 37 cents a share, compared with a loss of $21.2 million, or 35 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 36 cents a share.

The company said it expects milestones for its lead candidate, micvotabart pelidotin, this year, and remains on track to share updated monotherapy data in the middle of 2026 as well as updated combination data in the second half of the year.

Micvotabart pelidotin is designed to treat solid tumors, targeting a component of the tumor extracellular matrix.

The company expects to have cash runway into the fourth quarter.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

May 14, 2026 13:51 ET (17:51 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2635742250"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2635742250\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2635742250?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-15 01:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635742250","market":"sg","top_or_hot":-1,"title":"Pyxis Oncology Shares Slide on Steeper 1Q Loss","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/PYXS\">Pyxis Oncology</a> declined after the company logged a steeper first-quarter loss, narrowly missing Wall Street's expectations. \n</p>\n<p>\n  The stock slid 15% to $2.24 on Thursday. Shares have surged 94% year to date. \n</p>\n<p>\n  The company, which is developing cancer treatments, posted a loss of $23.3 million, or 37 cents a share, compared with a loss of $21.2 million, or 35 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 36 cents a share. \n</p>\n<p>\n  The company said it expects milestones for its lead candidate, micvotabart pelidotin, this year, and remains on track to share updated monotherapy data in the middle of 2026 as well as updated combination data in the second half of the year. \n</p>\n<p>\n  Micvotabart pelidotin is designed to treat solid tumors, targeting a component of the tumor extracellular matrix. \n</p>\n<p>\n  The company expects to have cash runway into the fourth quarter. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 14, 2026 13:51 ET (17:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pyxis Oncology Shares Slide on Steeper 1Q Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPyxis Oncology Shares Slide on Steeper 1Q Loss\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-05-15 01:51</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/PYXS\">Pyxis Oncology</a> declined after the company logged a steeper first-quarter loss, narrowly missing Wall Street's expectations. \n</p>\n<p>\n  The stock slid 15% to $2.24 on Thursday. Shares have surged 94% year to date. \n</p>\n<p>\n  The company, which is developing cancer treatments, posted a loss of $23.3 million, or 37 cents a share, compared with a loss of $21.2 million, or 35 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 36 cents a share. \n</p>\n<p>\n  The company said it expects milestones for its lead candidate, micvotabart pelidotin, this year, and remains on track to share updated monotherapy data in the middle of 2026 as well as updated combination data in the second half of the year. \n</p>\n<p>\n  Micvotabart pelidotin is designed to treat solid tumors, targeting a component of the tumor extracellular matrix. \n</p>\n<p>\n  The company expects to have cash runway into the fourth quarter. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 14, 2026 13:51 ET (17:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PYXS","symbol_name":"Pyxis Oncology, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2635742250","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635742250","pubTimestamp":1778781060,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Pyxis Oncology declined after the company logged a steeper first-quarter loss, narrowly missing Wall Street's expectations.The stock slid 15% to $2.24 on Thursday. Shares have surged 94% year to date.The company, which is developing cancer treatments, posted a loss of $23.3 million, or 37 cents a share, compared with a loss of $21.2 million, or 35 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 36 cents a share.The company said it expects milestones for its lead candidate, micvotabart pelidotin, this year, and remains on track to share updated monotherapy data in the middle of 2026 as well as updated combination data in the second half of the year.Micvotabart pelidotin is designed to treat solid tumors, targeting a component of the tumor extracellular matrix.The company expects to have cash runway into the fourth quarter.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PYXS":"Pyxis Oncology, Inc.","BK4139":"生物科技"},"translate_title":"Pyxis Oncology股价因第一季度亏损加剧而下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PYXS":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Shares of Pyxis Oncology declined after the company logged a steeper first-quarter loss, narrowly missing Wall Street's expectations. \n\n\n  The stock slid 15% to $2.24 on Thursday. Shares have surged 94% year to date. \n\n\n  The company, which is developing cancer treatments, posted a loss of $23.3 million, or 37 cents a share, compared with a loss of $21.2 million, or 35 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 36 cents a share. \n\n\n  The company said it expects milestones for its lead candidate, micvotabart pelidotin, this year, and remains on track to share updated monotherapy data in the middle of 2026 as well as updated combination data in the second half of the year. \n\n\n  Micvotabart pelidotin is designed to treat solid tumors, targeting a component of the tumor extracellular matrix. \n\n\n  The company expects to have cash runway into the fourth quarter. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 14, 2026 13:51 ET (17:51 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}